Evidence map›Paper›PMID 32143485›Full record

ArticleCells2020

Modulation of the Pol II CTD Phosphorylation Code by Rac1 and Cdc42 Small GTPases in Cultured Human Cancer Cells and Its Implication for Developing a Synthetic-Lethal Cancer Therapy.

Bo Zhang, Xuelin Zhong, Moira Sauane, Yihong Zhao, Zhi-Liang Zheng

Open access · goldAbstract read
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Bo ZhangDepartment of Biological Sciences, Lehman College, City University of New York, Bronx, NY 10468, USA.
Xuelin ZhongDepartment of Biological Sciences, Lehman College, City University of New York, Bronx, NY 10468, USA.
Moira SauaneDepartment of Biological Sciences, Lehman College, City University of New York, Bronx, NY 10468, USA.
Yihong ZhaoCenter of Alcohol and Substance Use Studies and Department of Applied Psychology, Graduate School of Applied and Professional Psychology, Rutgers University, Piscataway, NJ 08854, USA.
Zhi-Liang ZhengDepartment of Biological Sciences, Lehman College, City University of New York, Bronx, NY 10468, USA.ORCID 0000-0001-9908-6972
Lehman College · USThe Graduate Center, CUNY · USRutgers, The State University of New Jersey · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rho GTPases, including Rho, Cdc42, Rac and ROP subfamilies, are key signaling molecules in RNA polymerase II (Pol II) transcriptional control. Our prior work has shown that plant ROP and yeast Cdc42 GTPases similarly modulate Ser2 and Ser5 phosphorylation status of the C-terminal domain (CTD) of the Pol II largest subunit by regulating CTD phosphatase degradation. Here, we present genetic and pharmacological evidence showing that Cdc42 and Rac1 GTPase signaling modulates a similar CTD Ser2 and Ser5 phosphorylation code in cultured human cancer cells. While siRNA knockdown of

Indexed as

Carrier Proteinscdc42 GTP-Binding ProteinHumansMonomeric GTP-Binding ProteinsNeoplasmsrac1 GTP-Binding Proteinrho GTP-Binding ProteinsRNA Polymerase IISaccharomyces cerevisiaeSignal TransductionCarrier Proteinscdc42 GTP-Binding ProteinCDC42 protein, humanMonomeric GTP-Binding Proteinsrac1 GTP-Binding ProteinRAC1 protein, humanrho GTP-Binding ProteinsRNA Polymerase IIRPAP2 protein, humanCdc42CDK7CTD codeDOCK4DOCK9Pol IIRac1RhoTHZ1Torin1

Identifiers

PMID32143485
PMCPMC7140432
OpenAlexW3009906366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.